source
- AstraZeneca halts Phase 3 lung cancer trial of volrustomig after negative resultsAstraZeneca announced on Monday that it is ending the Phase 3 study of its lung-cancer drug volrustomig after the trial failed to meet its primary efficacy endpoints. The company said the data did…
- Experts say AI could outperform doctors on basic tasks by 2030Most clinical AI tools being built today are intended to work under a doctor's supervision. Healthcare and venture-capital experts predict that by 2030 AI may independently perform better than phy…